News

Teva and Active Biotech have announced the completion of patient enrollment for the second pivotal phase-III clinical trial, BRAVO. It is intended to evaluate oral once-daily immunomodulating compound,

Pfizer has announced the results from randomized phase-III trial of Sutent (sunitinib malate), in patients with advanced pancreatic islet cell tumors. Study demonstrated that median progression-free survival was

OXiGENE has initiated the phase-II study of vascular disrupting agent drug candidate, Zybrestat for ophthalmology in patients with polypoidal choroidal vasculopathy (PCV). The phase-II favor study is a

Inotek has reported positive top-line results from phase 1/2 randomized, double-blind, placebo-controlled clinical trial of INO-8875, in patients with glaucoma. The study showed that the treatment with INO-8875

Insmed has declared the results of phase-II clinical trial evaluating IPLEX (mecasermin rinfabate) in patients with myotonic muscular dystrophy (MMD). The randomized, double-blind, placebo-controlled trial conducted in 13

Intercell has announced that the US Centers for Disease Control and Prevention (CDC’) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations and include IXIARO,

Zila has entered into a merger agreement with Tolmar, a privately-held pharmaceutical research, development, manufacturing and commercial operations company. Under the terms of the agreement, Tolmar will acquire

OraSure has provided update regarding the status of its application for FDA approval of an OraQuick Hepatitis C (HCV) test, and its clinical program for an OraQuick HIV-1/2

Novartis’ new study demonstrated that treatment with Afinitor (everolimus) tablets, in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy, may have the potential to